Ezutromid - Summit Therapeutics

Drug Profile

Ezutromid - Summit Therapeutics

Alternative Names: BMN-195; SMT-1100; SMTC-1100; VOX-C1100

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VASTox
  • Developer Summit Therapeutics
  • Class Benzoxazoles; Naphthalenes; Small molecules; Sulfoxides
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 27 Mar 2018 Summit Therapeutics announces intention to submit regulatory application for marketing authorisation Duchenne muscular dystrophy
  • 07 Mar 2018 Summit Therapeutics expands enrolment in the phase II PhaseOut DMD trial in Duchenne muscular dystrophy to include patients who participated in phase I clinical trials of ezutromid but did not meet the entry criteria for the main PhaseOut DMD cohorts
  • 26 Feb 2018 Interim efficacy data from a phase II PhaseOut DMD trial in Duchenne muscular dystrophy released by Summit Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top